Hsp90 inhibitors: Clinical development and future opportunities in oncology therapy

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 193-202

  Gao, Zhenhai ^a   Garcia Echeverria, Carlos ^b   Jensen, Michael Rugaard ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; AT 13387; BIIB 021; BIIB 028; BORTEZOMIB; CYTARABINE; DOCETAXEL; EXEMESTANE; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IPI 493; IRINOTECAN; KW 2478; MPC 3100; NVP HSP 990; PACLITAXEL; PF 04929113; PF 4929113; RITUXIMAB; SNX 5422; SORAFENIB; STA 9090; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 888;

CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOLOGY; REVIEW;

ANIMALS; BENZOQUINONES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC;

EID: 77749270556     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Dutta R, Inouye M: GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci (2000) 25(1):24-28.
2. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, et al: The amino-terminal domain of heat shock protein 90 (Hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates Hsp90 conformation. J Biol Chem (1997) 272(38):23843-23850.
3. Pearl LH, Prodromou C: Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem (2001) 59:157-186.
4. Pearl LH, Prodromou C: Structure and in vivo function of Hsp90. Curr Opin Struct Biol (2000) 10(1):46-51.
5. Whitesell L, Lindquist SL: Hsp90 and the chaperoning of cancer. Nat Rev Cancer (2005) 5(10):761-772.
6. Diehl MC, Idowu MO, Kimmelshue K, York TP, Elmore LW, Holt SE.Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther (2009) 8(20):1952-1961.
7. Ferrarini M, Heltai S, Zocchi MR, Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer (1992) 51(4):613-619.
8. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA: Clinical and biological signifcance of Hsp89 α in human breast cancer. Int J Cancer (1992) 50(3):409-415.
9. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N: Herbimycin A induces the 20 S proteasome-and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem (1995) 270(28):16580-16587.
10. Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol (1995) 36(4):305-315.
11. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH: Geldanamycin, a new antibiotic. J Antibiot (Tokyo) (1970) 23(9):442-447.
12. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D: Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: Role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res (2005) 65(21):10006-10015.
13. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D: The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol (2006) 70(4):1194-1203.
14. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P: DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 91(22):1940-1949.
15. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem (2004) 12(20):5317-5329. (Pubitemid 39243952)
16. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA: In vivo antitumor effcacy of 17-DMAG (17-dimethylaminoethylamino- 17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol (2005) 56(2):115-125.
17. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 9(15):1479-1492.
18. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM: Reaction of geldanamycin and C17-substituted analogues with glutathione: Product identifcations and pharmacological implications. Chem Res Toxicol (2006) 19(3):376-381.
19. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J: Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel (2006) 9(4):483-495.
20. Drysdale MJ, Brough PA: Medicinal chemistry of Hsp90 inhibitors. Curr Top Med Chem (2008) 8(10):859-868.
21. Neckers L: Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol (2006) (172):259-277.
22. Taldone T, Gozman A, Maharaj R, Chiosis G: Targeting Hsp90: Small-molecule inhibitors and their clinical development. Curr Opin Pharmacol (2008) 8(4):370-374.
23. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 23(18):4152-4161. (Pubitemid 46211321)
24. Kosan Biosciences Inc: Kosan opens time-1 pivotal phase 3 trial in multiple myeloma. Press Release (2008): January 03.
25. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R et al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 14(23):7940-7946.
26. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J, Motzer RJ: A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs (2006) 24(6): 543-546.
27. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, et al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 14(24):8302-8307.
28. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF et al: Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J Clin Oncol (2007) 25(34):5410-5417.
29. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol (2009) 27(15s):Abs 8503.
30. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, et al: Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17- demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem (2006) 49(15):4606-4615.
31. Hanson BE, Vesole DH: Retaspimycin hydrochloride (IPI-504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs (2009) 18(9):1375-1383.
32. Sequist LV, Gettinger S, Natale R, Martins R, Lilenbaum R, Janne P, Gray J, Samuel TA, Grayzel D, Lynch TJ: A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratifed by EGFR mutation status. J Clin Oncol (2009) 27(15S):Abs 8073.
33. Infnity Pharmaceuticals Inc: Infnity halts RING trial in advanced gastrointestinal stromal tumors. Press Release (2009): July 14.
34. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N: Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER2 tyrosine kinase. Bioorg Med Chem (2002) 10(11): 3555-3564.
35. Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther (2009) 8(4):921-929.
36. Bryson JC, Infante JR, Ramanathan RK, Jones SF, Von Hoff DD, Burris HA: A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. J Clin Oncol (2008) 26(suppl):Abs 14613.
37. Houk BE, Bryson J, Egorin M, Ramanathan RK, Skillings J, Burris HA: Pharmacokinetics (PK) of PF-04929113 (SNX5422), and orally bioavailable heat shock protein 90 (Hsp90) inhibitor after single and multiple dose administration in patients with refractory solid tumor malignancies. American Association for Cancer Research, Denver, CO, USA (2009) 100:Abs 5443.
38. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfeld JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, et al: 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J Med Chem (2008) 51(2):196-218.
39. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res (2008) 68(8):2850-2860.
40. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, et al: NVP-AUY922: A small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res (2008) 10(2):R33.
41. Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR, Quadt C, Chène P, et al: Signalling profle and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia (2008) 22(8):1604-1612.
42. Ide S, Motwani M, Jensen MR, Wang J, Huseinovic N, Stiegler P, Wang X, Quadt C: Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol (2009) 27(15S):3533.
43. Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, et al: CUDC-305, a novel synthetic Hsp90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res (2009) 15(12): 4046-4057.
44. Barker JJ, Barker O, Boggio R, Chauhan V, Cheng RK, Corden V, Courtney SM, Edwards N, Falque VM, Fusar F, Gardiner M, et al: Fragment-based identifcation of Hsp90 inhibitors. ChemMedChem (2009) 4(6):963-966.
45. Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, et al: Combining hit identifcation strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d] pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem (2009) 52(15):4794-4809.
46. Cho-Schultz S, Patten MJ, Huang B, Elleraas J, Gajiwala KS, Hickey MJ, Wang J, Mehta PP, Kang P, Gehring MR, Kung PP, et al: Solution-phase parallel synthesis of Hsp90 inhibitors. J Comb Chem (2009) 11(5):860-874.
47. Cikotiene I, Kazlauskas E, Matuliene J, Michailoviene V, Torresan J, Jachno J, Matulis D: 5-Aryl-4-(5-substituted-2,4-dihydroxy-phenyl)-1,2,3- thiadiazoles as inhibitors of Hsp90 chaperone. Bioorg Med Chem Lett (2009) 19(4):1089-1092.
48. Duerfeldt AS, Brandt GE, Blagg BS: Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett (2009) 11(11):2353-2356.
49. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, et al: Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res (2007) 13(6):1769-1774. (Pubitemid 46952944)
50. Pacey SC, Wilson R, Walton M, Eatock M, Zetterlund A, Arkenau H, Beecham R, Raynaud F, Workman P, Judson I: A phase I trial of the Hsp90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J Clin Oncol (2009) 27(15S):3534.
51. Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla KN, Mita MM, Pluard TJ, Stiegler P, Quadt C, Shapiro GI: A phase I dose escalation study of AUY922, a novel Hsp90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2009) 27(15S):3532.
52. Bernstein SL, Russell P, Wong P, Fishelevich R, Smith LE: Heat shock protein 90 in retinal ganglion cells: Association with axonally transported proteins. Vis Neurosci (2001) 18(3):429-436.
53. Dean DO, Tytell M: Hsp25 and-90 immunoreactivity in the normal rat eye. Invest Ophthalmol Vis Sci (2001) 42(12):3031-3040.
54. Kosmaoglou M, Schwarz N, Bett JS, Cheetham ME: Molecular chaperones and photoreceptor function. Prog Retin Eye Res (2008) 27(4):434-449.
55. Lamb TD, Pugh EN Jr: Dark adaptation and the retinoid cycle of vision. Prog Retin Eye Res (2004) 23(3):307-380.
56. Anukanth A, Khorana HG: Structure and function in rhodopsin. Requirements of a specifc structure for the intradiscal domain. J Biol Chem (1994) 269(31):19738-19744.
57. Ficker E, Dennis A, Kuryshev Y, Wible BA, Brown AM: hHERG channel traffcking. Novartis Found Symp (2005) 266:57-69.
58. MacRae C, Richardson PG, Walker J, Grayzel DS, Demetri GD: Cardiovascular safety profle of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol (2009) 27(15S):e14539.
59. Li Y, Zhang T, Schwartz SJ, Sun D: New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 12(1-2):17-27.
60. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM: The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem (2000) 275(47):37181-37186.
61. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC, Altieri DC: Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA (2003) 100(24):13791-13796.
62. Pearl LH: Hsp90 and Cdc37-a chaperone cancer conspiracy. Curr Opin Genet Dev (2005) 15(1):55-61.
63. Suriawinata A: Survivin: Apoptosis inhibitor and its regulation by Hsp90. Lab Invest (2004) 84(4):395.
64. Donnelly A, Blagg BS: Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 15(26):2702-2717.
65. Li Y, Zhang T, Jiang Y, Lee H F, Schwartz SJ, Sun D: (-)- Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm (2009) 6(4):1152-1159.
66. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G: The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review. Pharmacol Ther (1998) 79(2):129-168.
67. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BS: Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem (2008) 73(6):2130-2137.
68. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS: Hsp90 inhibitors identifed from a library of novobiocin analogues. J Am Chem Soc (2005) 127(37):12778-12779.
69. Pan Z, Erkan M, Streit S, Friess H, Kleeff J: Silencing of Grp94 expression promotes apoptosis in pancreatic cancer cells. Int J Oncol (2009) 35(4):823-828.
70. Sheu ML, Liu SH, Lan KH: Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth. PLoS One (2007) 2(10):e1096.
71. Dollins DE, Warren JJ, Immormino RM, Gewirth DT: Structures of Grp94-nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones. Mol Cell (2007) 28(1):41-56.
72. Ostrovsky O, Makarewich CA, Snapp EL, Argon Y: An essential role for ATP binding and hydrolysis in the chaperone activity of Grp94 in cells. Proc Natl Acad Sci USA (2009) 106(28):11600-11605.
73. Rosser MF, Nicchitta CV: Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, Grp94. I. Evidence for allosteric regulation of ligand binding. J Biol Chem (2000) 275(30):22798-22805.
74. Soldano KL, Jivan A, Nicchitta CV, Gewirth DT: Structure of the N-terminal domain of Grp94. Basis for ligand specifcity and regulation. J Biol Chem (2003) 278(48):48330-48338.
75. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F, Landriscina M: TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett (2009) 279(1):39-46.
76. Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, Landriscina M, Esposito F: Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress (2007) 10(4):342-350.
77. Gao Z, Fong S: Assay development for heat shock proteins. In: A Practical Guide to Assay Development and High-throughput Screening in Drug Discovery. Chen T, Czarnik AW, Bing Y (Eds), CRC Press, Boca Raton, FL, USA (2009):83-98.
78. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN et al: Gene expression signature-based chemical genomic prediction identifes a novel class of Hsp90 pathway modulators. Cancer Cell (2006) 10(4):321-330.
79. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D: A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 7(1):162-170.
80. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D: Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. J Biol Chem (2009) 284(51):35381-35389.
81. Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG, Sun D: Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2009) 79(4): 542-551.
82. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW, Prodromou C, Pearl LH: The mechanism of Hsp90 regulation by the protein kinase-specifc cochaperone p50(Cdc37). Cell (2004) 116(1):87-98.
83. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C, Robinson CV, Saibil HR, Pearl LH: Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell (2006) 23(5):697-707.
84. Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C: The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors. Exp Hematol (2008) 36(10):1266-1277.
85. Yi F, Zhu P, Southall N, Inglese J, Austin CP, Zheng W, Regan L: An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J Biomol Screen (2009) 14(3):273-281.
86. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 7(5):457-468.
87. Lang W, Caldwell GW, Li J, Leo GC, Jones WJ, Masucci JA: Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: Reductive versus oxidative metabolism and implications. Drug Metab Dispos (2007) 35(1):21-29.